Journal
HEPATOLOGY
Volume 65, Issue 1, Pages 350-362Publisher
WILEY
DOI: 10.1002/hep.28709
Keywords
-
Categories
Funding
- Fondo Nacional De Ciencia y Tecnologia de Chile (FONDECYT) [1150327]
- Comision Nacional de Investigacion, Ciencia y Tecnologia (CONICYT) [PFB 12/2007 CARE Chile UC]
- Austrian Science Foundation (FWF) [F3008-B19, F3517-B20]
- Vienna Science and Technology Fund [LS12-008]
- Medical Scientific Fund of the Mayor of the City of Vienna [12040]
- NIH [DK56239, DK47987]
- Austrian Science Fund (FWF) [F 3008] Funding Source: researchfish
Ask authors/readers for more resources
Nonalcoholic fatty liver disease (NAFLD) is a burgeoning health problem worldwide and an important risk factor for both hepatic and cardiometabolic mortality. The rapidly increasing prevalence of this disease and of its aggressive form nonalcoholic steatohepatitis (NASH) will require novel therapeutic approaches to prevent disease progression to advanced fibrosis or cirrhosis and cancer. In recent years, bile acids have emerged as relevant signaling molecules that act at both hepatic and extrahepatic tissues to regulate lipid and carbohydrate metabolic pathways as well as energy homeostasis. Activation or modulation of bile acid receptors, such as the farnesoid X receptor and TGR5, and transporters, such as the ileal apical sodium- dependent bile acid transporter, appear to affect both insulin sensitivity and NAFLD/ NASH pathogenesis at multiple levels, and these approaches hold promise as novel therapies. In the present review, we summarize current available data on the relationships of bile acids to NAFLD and the potential for therapeutically targeting bile- acid- related pathways to address this growing world- wide disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available